The extension round was led by Forward Partners and MMC Ventures to support ongoing growth.
"We are excited to announce this investment which is a huge statement of confidence from our investors that we have a unique approach to solving a major global problem in healthcare – how to truly increase access and treat people faster, without adding further burden onto clinicians. We are thrilled to add Simplyhealth Ventures and look forward to working with them as we look forward to growing in the UK and beyond in the next 12 months."
Oppenheimer led the Series C financing, which will support US expansion and the development of new diagnostic tools.
"The second Series C second close further supports deployment, development and validation of our platform-based product portfolio targeted for clinical research and clinical use,"
The financing round was led by Incisive Ventures with participation from a broad syndicate of institutional and retail backers.
"Millions of people are seeking an easy way to feel less stressed and anxious and we’ve seen increasing demand for our product. In the second half of 2022 we grew almost 300% and this round will allow us to scale and serve even more people,"
Oxford Innovation and OION angels have backed Cognitant Group in a follow-on funding round.
"We are focused on making it easier for patients to understand their symptoms and management of their individual condition. This not only has a positive impact on their overall health, but it also allows them to successfully make decisions about their individual treatment plans in collaboration with their clinicians. Our partnerships with global pharmaceutical companies, the NHS and other healthcare providers, is making real and valuable changes to the way patients engage with and manage their health."
The financing was supported by new investors including InnoSpark alongside returning backers such as the Development Bank of Wales.
"This is the most comprehensive validation of our platform thus far. While identifying antibodies to GPCRs has traditionally been a complex and time-intensive process requiring expensive specialist technology and training, we have demonstrated that Antiverse’s drug discovery platform can achieve this in a fraction of the time and cost. GPCRs are commercially interesting targets associated with various indications, and these antibodies offer a path to first in vivo results and can potentially be our first assets. I would like to thank our investors, this funding will enable us to continue to develop these assets in-house with our academic collaborators."
.png)
